UCB (OTCMKTS:UCBJY) Upgraded at Jefferies Financial Group

UCB (OTCMKTS:UCBJY) was upgraded by Jefferies Financial Group from a “moderate sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Other analysts have also issued research reports about the company. Barclays lowered UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Zacks Research upgraded UCB from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

UCB Stock Down 0.9%

Shares of UCBJY opened at $127.41 on Monday. The company has a quick ratio of 1.04, a current ratio of 1.38 and a debt-to-equity ratio of 0.20. UCB has a twelve month low of $106.09 and a twelve month high of $168.76. The company has a 50 day moving average of $143.25 and a 200-day moving average of $147.27.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.